Citations

Clear

367 citation(s) found for "Du, Pan".

CRRL269: a novel designer and renal-enhancing pGC-A peptide activator
Chen, Yang, Harty, Gail J., Huntley, Brenda K., Heublein, Denise M., Harders, Gerald E., Meems, Laura M.G., Pan, Shuchong, Sangaralingham, S. Jeson , Ichiki, Tomoko , Burnett, John C. , Iyer, Seethalakshmi R., Meems, Laura, Chen, Yang, Iyer, Seethalakshmi , Sangaralingham, S. Jeson

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | November 29, 2017 | Volume: 314 | Issue: 3 | Pages: R407-R414

10.1152/ajpregu.00286.2017 | PMID 29187381 Get It

The natriuretic peptides (NPs) B-type NP (BNP) and urodilatin (URO) exert renal protective properties via the particulate guanylyl cyclase A receptor (pGC-A). As a potential renal-enhancing strategy, we engineered a novel designer peptide that we call CRRL269. CRRL269 was investigated in human cell lines and in normal canines to define potential cardiorenal enhancing actions. The mechanism of its cardiorenal selective properties was also investigated. In vitro NP receptor activity was quantified with guanosine 3′,5′-cyclic monophosphate generation. In vivo effects were determined in normal canine acute infusion studies. We observed that CRRL269 demonstrated enhanced pGC-A activity in renal compared with nonrenal cell lines. CRRL269 exerted enhanced resistance to neprilysin compared with URO. Importantly, CRRL269 exhibited significant and greater increases in urinary sodium excretion and diuresis, with less blood pressure reduction, than BNP or URO in normal canines. CRRL269 retained potent renin-angiotensin-aldosterone system (RAAS) suppressing properties shared by URO and BNP. Also, CRRL269 exerted less arterial relaxation and higher cAMP cardiomyocytes generation than BNP. CRRL269 possessed superior renal and pGC-A activating properties compared with BNP or URO in vitro. CRRL269 exerted enhanced renal actions while suppressing RAAS in vivo and with less hypotension compared with URO or BNP. Together, our study suggests that CRRL269 is a promising innovative renal-enhancing drug, with favorable protective actions targeting cardiorenal disease states through the pGC-A receptor.
PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer
Yang, Yinhui , He, Yundong , Chen, Jiaxiang , Pan, Yunqian , Hinten, Michael, Karnes, R. Jeffrey , Westendorf, Jennifer J., Li, Benyi , Zhu, Runzhi , Xu, Wanhai , Kohli, Manish , Bai, Yang , Zhao, Yu , Ma, Linlin , Zhang, Jun , Westendorf, Jennifer J. , Huang, Haojie

Mayo Clinic

Clinical Cancer Research | November 22, 2017 | Volume: 24 | Issue: 4 | Pages: 834-846

10.1158/1078-0432.ccr-17-2006 | PMID 29167276 Get It

Abstract Purpose: Intratumoral androgen synthesis (IAS) is a key mechanism promoting androgen receptor (AR) reactivation and antiandrogen resistance in castration-resistant prostate cancer (CRPC). However, signaling pathways driving aberrant IAS remain poorly understood. Experimental Design: The effect of components of the AKT-RUNX2-osteocalcin (OCN)–GPRC6A–CREB signaling axis on expression of steroidogenesis genes CYP11A1 and CYP17A1 and testosterone level were examined in PTEN-null human prostate cancer cell lines. Pten knockout mice were used to examine the effect of Runx2 heterozygous deletion or abiraterone acetate (ABA), a prodrug of the CYP17A1 inhibitor abiraterone on Cyp11a1 and Cyp17a1 expression, testosterone level and tumor microenvironment (TME) remodeling in vivo. Results: We uncovered that activation of the AKT–RUNX2–OCN–GPRC6A–CREB signaling axis induced expression of CYP11A1 and CYP17A1 and testosterone production in PTEN-null prostate cancer cell lines in culture. Deletion of Runx2 in Pten homozygous knockout prostate tumors decreased Cyp11a1 and Cyp17a1 expression, testosterone level, and tumor growth in castrated mice. ABA treatment also inhibited testosterone synthesis and alleviated Pten loss-induced tumorigenesis in vivo. Pten deletion induced TME remodeling, but Runx2 heterozygous deletion or ABA treatment reversed the effect of Pten loss by decreasing expression of the collagenase Mmp9. Conclusions: Abnormal RUNX2 activation plays a pivotal role in PTEN loss-induced IAS and TME remodeling, suggesting that the identified signaling cascade represents a viable target for effective treatment of PTEN-null prostate cancer, including CRPC. Clin Cancer Res; 24(4); 834–46. ©2017 AACR.
Loss of FOXO1 Cooperates with TMPRSS2–ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion
Yang, Yinhui , Blee, Alexandra M. , Wang, Dejie , An, Jian , Pan, Yunqian , Yan, Yuqian , He, Yundong , Dugdale, Joseph , Hou, Xiaonan , Zhang, Jun , Weroha, S. John , Zhu, Wei‐Guo , Wang, Yanru , DePinho, Ronald A. , Xu, Wanhai , DePinho, Ronald A , Ma, Tao , Huang, Haojie

Mayo Clinic

Cancer Research | October 6, 2017 | Volume: 77 | Issue: 23 | Pages: 6524-6537

10.1158/0008-5472.can-17-0686 | PMID 28986382 Get It

Abstract E26 transformation-specific transcription factor ERG is aberrantly overexpressed in approximately 50% of all human prostate cancer due to TMPRSS2-ERG gene rearrangements. However, mice with prostate-specific transgenic expression of prostate cancer–associated ERG alone fail to develop prostate cancer, highlighting that ERG requires other lesions to drive prostate tumorigenesis. Forkhead box (FOXO) transcription factor FOXO1 is a tumor suppressor that is frequently inactivated in human prostate cancer. Here, we demonstrate that FOXO1, but not other FOXO proteins (FOXO3 and FOXO4), binds and inhibits the transcriptional activity of prostate cancer–associated ERG independently of FOXO1 transcriptional activity. Knockdown of endogenous FOXO1 increased invasion of TMPRSS2–ERG fusion–positive VCaP cells, an effect completely abolished by ERG knockdown. Patient specimen analysis demonstrated that FOXO1 and ERG protein expression inversely correlated in a subset of human prostate cancer. Although human ERG transgene expression or homozygous deletion of Foxo1 alone in the mouse prostate failed to promote tumorigenesis, concomitant ERG transgene expression and Foxo1 deletion resulted in upregulation of ERG target genes, increased cell proliferation, and formation of high-grade prostatic intraepithelial neoplasia. Overall, we provide biochemical and genetic evidence that aberrantly activated ERG cooperates with FOXO1 deficiency to promote prostate tumorigenesis and cell invasion. Our findings enhance understanding of prostate cancer etiology and suggest that the FOXO1–ERG signaling axis can be a potential target for treatment of prostate cancer. Cancer Res; 77(23); 6524–37. ©2017 AACR.
Abstract 628: Neoantigens predicted by clonal mutation analysis in lung adenocarcinoma patients
Cai, Weijing, Ling, Tan Wen, Zhou, Caichun, Lou, Yanyan , Zhou, Dapeng , Pan, Deng , Wang, Jiaqian

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 628-628

10.1158/1538-7445.am2017-628 Get It

Abstract Mutant peptides presented in cancer are superior vaccine candidates than self peptides. The efficacy of mutant K-Ras, P53 and EFGR peptides have been tested as cancer vaccines in pancreatic cancer, colorectal cancer, and lung adenocarcinoma. However, the occurrence of these mutations in cancer is limited. Further more, these mutant peptides can only be presented by certain MHC alleles. Neoantigens expressed by passenger mutations which are not involved in common proliferative molecular pathways are potential candidates for personalized vaccine design. Such passenger mutations have drawn attention by the recent clinical data that colorectal cancer with a large number of somatic mutations due to mismatch-repair defects are more susceptible to immune checkpoint blockade by PD1 antibody therapy. In this study, we analyzed the next generation sequencing data of 147 lung adenocarcinoma patients from The Cancer Genome Atlas and predicted neoantigens presented by MHC Class I and Class II molecules. We found 18175 expressed clonal somatic mutations, with an average of 124 per patient. Based on such somatic mutations, we predicted 8731 neo-peptides, among which 3888 strong-binders and 4843 weak-binders to MHC Class I molecules were found by NetMHCPan. For HLA-A*02:01, 778 strong binding and 822 weak binding neo-peptides were found. In average, 11 neo-antigen peptides of mutations were predicted per individual patient with HLA-A*02:01 allele. Smokers expressed 5.73 fold higher mutant neo-antigen peptides than non-smokers. The 20 most commonly mutated genes with predicted neo-antigens are TTN, RYR2, MUC16, KRAS, ZFHX4, TP53, USH2A, NAV3, KEAP1, ANK2, DNAH9, ADAMTS12, CSMD1, CSMD3, SPTA1, FAT3, ZNF804A, PAPPA2, PCLO, EGFR. As a positive control, the frequency of known proliferation-related mutations (KRAS, P53, and EGFR) were determined in 147 patients, which are consistent with previously next generation sequencing studies of lung adenocarcinoma. Mutation hotspots were found in proliferation-related mutations (KRAS), but not in passenger mutations. 6950 neo-peptides, including 259 strong binders and 6691 weak binders were found for HLA DRB1, an MHC Class II molecule. INDEL mutation type of neo-epitopes were found in 119 of 147 patients, with an average of 4.34 INDEL mutations presented by MHC Class I and 0.86 INDEL mutations presented by MHC Class II molecule HLA DRB1 in every patient. Our results support the feasibility of discovering individualized mutant peptides as candidates for immunodiagnosis and immunotherapy of lung adenocarcinoma. Neo-epitopes which can be presented by both MHC Class I and MHC Class II molecules are attractive targets for designing long-peptide vaccines. Note: This abstract was not presented at the meeting. Citation Format: Dapeng Zhou, Weijing Cai, Deng Pan, Tan Wen Ling, Jiaqian Wang, Caichun Zhou, Yanyan Lou. Neoantigens predicted by clonal mutation analysis in lung adenocarcinoma patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 628. doi:10.1158/1538-7445.AM2017-628
Pathology Imagebase—a reference image database for standardization of pathology
Egevad, Lars , Cheville, John C. , Evans, Andrew , Hörnblad, Jonas, Kench, James G. , Leite, Kátia Ramos Moreira , Pan, Chin‐Chen , Samaratunga, Hemamali , Srigley, John R., True, Lawrence D. , Zhou, Ming , Clements, Mark , Delahunt, Brett , Panel, The ISUP Pathology Imagebase Expert, Cheng, Liang , López-Beltrán, Antonio , Távora, Fábio , Netto, George J. , Tsuzuki, Toyonori , Pan, Chin-Chen , Delahunt, Brett , Kristiansen, Glen , Magi‐Galluzzi, Cristina , Panel, The ISUP Pathology Imagebase Expert, Tsuzuki, Toyonori , Samaratunga, Hemamali , Cheng, Liang

Mayo Clinic

Histopathology | July 19, 2017 | Volume: 71 | Issue: 5 | Pages: 677-685

10.1111/his.13313 | PMID 28722802 Get It

AimsDespite efforts to standardize histopathology practice through the development of guidelines, the interpretation of morphology is still hampered by subjectivity. We here describe Pathology Imagebase, a novel mechanism for establishing an international standard for the interpretation of pathology specimens.Methods and resultsThe International Society of Urological Pathology (ISUP) established a reference image database through the input of experts in the field. Three panels were formed, one each for prostate, urinary bladder and renal pathology, consisting of 24 international experts. Each of the panel members uploaded microphotographs of cases into a non‐public database. The remaining 23 experts were asked to vote from a multiple‐choice menu. Prior to and while voting, panel members were unable to access the results of voting by the other experts. When a consensus level of at least two‐thirds or 16 votes was reached, cases were automatically transferred to the main database. Consensus was reached in a total of 287 cases across five projects on the grading of prostate, bladder and renal cancer and the classification of renal tumours and flat lesions of the bladder. The full database is available to all ISUP members at www.isupweb.org. Non‐members may access a selected number of cases.ConclusionsIt is anticipated that the database will assist pathologists in calibrating their grading, and will also promote consistency in the diagnosis of difficult cases.
Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction
Jin, Xin , Pan, Yunqian , Wang, Liguo , Zhang, Lizhi , Tang, Amy , Billadeau, Daniel D. , Wu, Heshui , Ma, Tao , Huang, Haojie , Wang, Liguo , Tang, Amy H , Jin, Xin

Mayo Clinic

Cancer Research | July 18, 2017 | Volume: 77 | Issue: 16 | Pages: 4328-4341

10.1158/0008-5472.can-16-3143 | PMID 28720574 Get It

Abstract Dysregulation of the MAPK pathway correlates with progression of pancreatic ductal adenocarcinoma (PDAC) progression. IQ motif containing GTPase-activating protein 1 (IQGAP1) is a MAPK scaffold that directly regulates the activation of RAF, MEK, and ERK. Fructose-1,6-bisphosphatase (FBP1), a key enzyme in gluconeogenesis, is transcriptionally downregulated in various cancers, including PDAC. Here, we demonstrate that FBP1 acts as a negative modulator of the IQGAP1–MAPK signaling axis in PDAC cells. FBP1 binding to the WW domain of IQGAP1 impeded IQGAP1-dependent ERK1/2 phosphorylation (pERK1/2) in a manner independent of FBP1 enzymatic activity. Conversely, decreased FBP1 expression induced pERK1/2 levels in PDAC cell lines and correlated with increased pERK1/2 levels in patient specimens. Treatment with gemcitabine caused undesirable activation of ERK1/2 in PDAC cells, but cotreatment with the FBP1-derived small peptide inhibitor FBP1 E4 overcame gemcitabine-induced ERK activation, thereby increasing the anticancer efficacy of gemcitabine in PDAC. These findings identify a primary mechanism of resistance of PDAC to standard therapy and suggest that the FBP1–IQGAP1–ERK1/2 signaling axis can be targeted for effective treatment of PDAC. Cancer Res; 77(16); 4328–41. ©2017 AACR.
Cryoballoon ablation in Chinese patients with paroxysmal atrial fibrillation: 1‐year follow‐up
Ling, Tianyou , Pan, Wenqi , Lin, Changjian , Lee, Hon‐Chi, Wu, Liqun , Ling, Tian-You , Jin, Qi , Zhang, Ning

Mayo Clinic

Pacing and Clinical Electrophysiology | July 13, 2017 | Volume: 40 | Issue: 10 | Pages: 1067-1072

10.1111/pace.13157 | PMID 28703873 Get It

AbstractObjectivesWe assessed the effectiveness and safety of cryoballoon ablation (CBA) in the Chinese population with paroxysmal atrial fibrillation (AF) with a 1‐year follow‐up and determined the association of early recurrence of atrial tachyarrhythmias (ERAT) with late recurrence (LR).MethodsA total of 114 patients (age 61 ± 10 years, 78 males) with paroxysmal AF who underwent CBA were consecutively enrolled. After procedures, patients were observed for 3 days with continuous electrocardiogram monitoring in the hospital with routine follow‐up visits at 3 months, 6 months, and 1 year. Documented atrial tachyarrhythmia >30 seconds was defined as recurrence. ERAT was defined as any recurrence during the first 3 months, and LR was recurrence between 3 and 12 months.ResultsWith the first 3 months as blanking period, 76% of patients were free of LR at 12 months. Five patients (4%) experienced complications, including phrenic nerve palsy, stroke, and groin complications. Forty‐five percent of patients had ERAT in the first 3 months and 31% of patients had ERAT in the first 3 days. Patients with ERAT had higher LR rate (LRR) than those without ERAT (43% vs 8%, P < 0.001). The LRR of patients with ERAT only in the first 3 days was lower than those with ERAT both in the first 3 days and in 4–90 days (29% vs 64%, P = 0.036).ConclusionsCBA was an effective and safe treatment option for paroxysmal AF. Patients with ERAT had higher LRR after CBA of AF. The time when ERAT occurred had an impact on LRR.
Erratum to: Development of a Unifying Target and Consensus Indicators for Global Surgical Systems Strengthening: Proposed by the Global Alliance for Surgery, Obstetric, Trauma, and Anaesthesia Care (The G4 Alliance)
Haider, Adil H. , Scott, John W. , Gause, Colin D., Meheš, Mira, Hsiung, Grace, Prelvukaj, Albulena, Yanocha, Dana, Baumann, Lauren M., Ahmed, Faheem , Ahmed, Naeem , Anderson, Sara, Angaté, Hervé, Arfaa, Lisa, Asbun, Horacio J. , Ashengo, Tigistu Adamu , Asuman, Kisembo, Bickler, Stephen W. , Billingsley, Saul, Bird, Peter, Botman, Matthijs , Butler, Marilyn, Buyske, Jo, Capozzi, Angelo, Casey, Kathleen , Clayton, Charles, Cobey, James C., Cotton, Michael , Deckelbaum, Dan, Derbew, Miliard , deVries, Catherine R. , Dillner, Jeanne, Downham, Max, Draisin, Natalie, Echinard, David, Elneil, Sohier , ElSayed, Ahmed , Estelle, Abigail, Finley, G. Allen , Frenkel, Erica, Frykman, Philip K., Gheorghe, Florin, Gore‐Booth, Julian, Henker, Richard , Henry, Jaymie , Henry, Orion, Hoemeke, Laura , Ibanga, Iko, Jackson, Eric V., Jani, Pankaj , Johnson, Walter D. , Jones, Andrew , Kassem, Zeina, Kocan, Abbey, Krishnaswami, Sanjay , Lane, Robert H. , Latif, Asad , Levy, Barbara , Linos, Dimitrios , Linz, Peter E., Listwa, Louis A., Magee, Declan, Makasa, Emmanuel , Marin, Michael L. , Martin, Claude , McQueen, Kelly, Morgan, Jamie , Moser, Richard , Neighbor, Robert, Novick, William M. , Ogendo, Stephen, Omigbodun, Akinyinka , Onajin‐Obembe, Bisola , Parsan, Neil, Philip, Beverly K., Price, Raymond R. , Rasheed, Shahnawaz, Ratel, M, Reynolds, Cheri, Roser, Steven M. , Rowles, Jackie , Samad, Lubna , Sampson, John , Sanghvi, Harshadkumar, Sellers, Marchelle L., Sigalet, David L. , Steffes, Bruce C., Stieber, Erin, Swaroop, Mamta , Tarpley, John L. , Varghese, Asha , Varughese, Julie, Wagner, Richard, Warf, Benjamin C. , Wetzig, Neil , Williamson, Susan , Wood, Joshua, Zeidan, Anne, Zirkle, Lewis G. , Allen, Brendan, Abdullah, Fizan , Asbun, Horacio, Ayala, Ruben , Butler, Marilyn, Gheorghe, Florin, Hoffman, David C. , Lane, Robert, Varughese, Julie

Mayo Clinic

World Journal of Surgery | June 22, 2017 | Volume: 41 | Issue: 10 | Pages: 2423-2425

10.1007/s00268-017-4067-7 | PMID 28642965 Get It

Development of a Unifying Target and Consensus Indicators for Global Surgical Systems Strengthening: Proposed by the Global Alliance for Surgery, Obstetric, Trauma, and Anaesthesia Care (The G4 Alliance)
Haider, Adil H. , Scott, John W. , Gause, Colin D., Meheš, Mira, Hsiung, Grace, Prelvukaj, Albulena, Yanocha, Dana, Baumann, Lauren M., Ahmed, Faheem , Ahmed, Naeem , Anderson, Sara, Angaté, Hervé, Arfaa, Lisa, Asbun, Horacio J. , Ashengo, Tigistu Adamu , Asuman, Kisembo, Ayala, Ruben , Bickler, Stephen W. , Billingsley, Saul, Bird, Peter, Botman, Matthijs , Butler, Marilyn, Buyske, Jo, Capozzi, Angelo, Casey, Kathleen , Clayton, Charles, Cobey, James C., Cotton, Michael , Deckelbaum, Dan, Derbew, Miliard , deVries, Catherine R. , Dillner, Jeanne, Downham, Max, Draisin, Natalie, Echinard, David, Elneil, Sohier , ElSayed, Ahmed , Estelle, Abigail, Finley, G. Allen , Frenkel, Erica, Frykman, Philip K., Gheorghe, Florin, Gore‐Booth, Julian, Henker, Richard , Henry, Jaymie , Henry, Orion, Hoemeke, Laura , Ibanga, Iko, Jackson, Eric V., Jani, Pankaj , Johnson, Walter D. , Jones, Andrew , Kassem, Zeina, Kocan, Abbey, Krishnaswami, Sanjay , Lane, Robert H. , Latif, Asad , Levy, Barbara , Linos, Dimitrios , Linz, Peter E., Listwa, Louis A., Magee, Declan, Makasa, Emmanuel , Marin, Michael L. , Martin, Claude , McQueen, Kelly, Morgan, Jamie , Moser, Richard , Neighbor, Robert, Novick, William M. , Ogendo, Stephen, Omigbodun, Akinyinka , Onajin‐Obembe, Bisola , Parsan, Neil, Philip, Beverly K., Price, Raymond R. , Rasheed, Shahnawaz, Ratel, M, Reynolds, Cheri, Roser, Steven M. , Rowles, Jackie , Samad, Lubna , Sampson, John , Sanghvi, Harshadkumar, Sellers, Marchelle L., Sigalet, David L. , Steffes, Bruce C., Stieber, Erin, Swaroop, Mamta , Tarpley, John L. , Varghese, Asha , Varughese, Julie, Wagner, Richard, Warf, Benjamin C. , Wetzig, Neil , Williamson, Susan , Wood, Joshua, Zeidan, Anne, Zirkle, Lewis G. , Allen, Brendan, Abdullah, Fizan , Asbun, Horacio, Butler, Marilyn, Gheorghe, Florin, Hoffman, David C. , Lane, Robert, Varughese, Julie

Mayo Clinic

World Journal of Surgery | May 15, 2017 | Volume: 41 | Issue: 10 | Pages: 2426-2434

10.1007/s00268-017-4028-1 | PMID 28508237 Get It

AbstractAfter decades on the margins of primary health care, surgical and anaesthesia care is gaining increasing priority within the global development arena. The 2015 publications of the Disease Control Priorities third edition on Essential Surgery and the Lancet Commission on Global Surgery created a compelling evidenced‐based argument for the fundamental role of surgery and anaesthesia within cost‐effective health systems strengthening global strategy. The launch of the Global Alliance for Surgical, Obstetric, Trauma, and Anaesthesia Care in 2015 has further coordinated efforts to build priority for surgical care and anaesthesia. These combined efforts culminated in the approval of a World Health Assembly resolution recognizing the role of surgical care and anaesthesia as part of universal health coverage. Momentum gained from these milestones highlights the need to identify consensus goals, targets and indicators to guide policy implementation and track progress at the national level. Through an open consultative process that incorporated input from stakeholders from around the globe, a global target calling for safe surgical and anaesthesia care for 80% of the world by 2030 was proposed. In order to achieve this target, we also propose 15 consensus indicators that build on existing surgical systems metrics and expand the ability to prioritize surgical systems strengthening around the world.
Analysis of Reach-to-Grasp by School-Aged Children with Down Syndrome Elucidates Limitations in Upper Extremity Motor Control
Valvano, Joanne, Hogy, Sara M., Worster, Kate, Ma, Julie , Denniston, Nancy L., Winders, Patricia C. , Rapport, Mary Jane, Pan, Zhaoxing , Carollo, James, Hogy, Sara

Mayo Clinic

Physical & Occupational Therapy In Pediatrics | February 3, 2017 | Volume: 37 | Issue: 4 | Pages: 374-388

10.1080/01942638.2016.1261979 | PMID 28157417 Get It